Previous 10 | Next 10 |
Soligenix (NASDAQ: SNGX ) will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of ~$600,000 over 3 years. More news on: Soligenix, Inc., Healthcare stocks news, Read more .....
PRINCETON, N.J. , May 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Solige...
Soligenix (NASDAQ: SNGX ): Q1 GAAP EPS of -$0.09 beats by $0.05 . More news on: Soligenix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PRINCETON, N.J. , May 14, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its re...
PRINCETON, N.J. , April 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an...
Thinly traded nano cap Soligenix (NASDAQ: SNGX ) is up 16% premarket on light volume in response to its announcement that enrollment in its Phase 3 clinical trial, DOM-INNATE , evaluating SGX942 for the treatment of oral mucositis (OM) in head and neck cancer patients has reac...
PRINCETON, N.J. , April 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today th...
Soligenix (NASDAQ: SNGX ) has received approx. $611,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program. More news on: Soligenix, Inc., Healthcare stocks news, Read more ...
PRINCETON, N.J. , April 15, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it h...
The Pediatric Committee (PDCO) of the EMA has agreed to Soligenix's (NASDAQ: SNGX ) Pediatric Investigation Plan (PIP) for SGX942 (dusquetide). The Company may defer conducting the PIP until successful completion of Phase 3 clinical study evaluating SGX942 as a treatment for oral mucositis...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK and PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, is making significant strides in the treatment of Cutaneous T-Cell Lymphoma (CTCL) with its investigational drug, HyBryte™. In an exclusive...
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's ( Nasdaq:SNGX ) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte...